FDA Clears Updated Software for Faster Low-Field MRI Brain Scans
The ninth FDA clearance for the Swoop Portable MR Imaging system is for new software that enables significant scan time reduction for brain MRI scans.
The Swoop Portable MR Imaging system has garnered another FDA 510(k) clearance for new software that may facilitate more expedient diagnosis of neurological conditions.
The updated software reportedly offers significant reduction of scan times, facilitating use of the device’s ultra-low-field magnetic resonance imaging (MRI) capabilities in acute care settings, according to Hyperfine, the manufacturer of the Swoop Portable MR Imaging system.
A newly FDA-cleared software update for the Swoop Portable MR Imaging system facilitates significantly reduced scan times for low-field MRI brain imaging, according to Hyperfine, the manufacturer of the MRI system. (Image courtesy of Hyperfine.)
“Timely MR brain imaging is essential for clinicians making critical treatment decisions, particularly in acute neurological episodes like strokes. We have been an active site in the ACTION PMR study assessing the use of the Swoop® system in stroke diagnosis, and this latest software will help the Swoop® system more seamlessly integrate into stroke workflows,” noted Adnan Siddiqui, M.D., Ph.D., a professor and vice-chairman in the Department of Neurosurgery at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences.
Hyperfine added that the reduced acquisition time for MRI sequences with the new software may help mitigate the impact of patient motion on brain scan quality.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
